VERU · Veru Inc. · Webcasts, Transcripts & Audio
$2.47
-0.08 (-3.14%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of the financial statements included in this report. Certain elements of our operating plan to alleviate the conditions that raise substantial doubt, including but not limited to our ability to secure equity financing or other financing alternatives, are outside of our control and cannot be included in management's evaluation under the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of the financial statements included in this report.”View the 10-Q filed Aug 10, 2026
Market Cap
$43.31M
Shares
17.05M
Volume · Oct 6
1.52M
Avg daily vol (3M)
252.25K
Veru Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Veru Inc. (VERU), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼2.3%
$13.03M
−$14.18M
'22 Q2
22-05-12
▼45.6%
$9.60M
−$22.20M
'22 Q3
22-08-11
▼83.5%
$2.59M
−$41.29M
'22 Q4
22-12-05
▼82.3%
$2.51M
−$38.71M
'23 Q1
23-02-09
▼49.4%
$6.59M
−$33.79M
'23 Q2
23-05-11
▼65.2%
$3.34M
−$12.52M
'23 Q3
23-08-10
▼14.6%
$2.14M
−$8.28M
'24 Q1
24-02-08
▼37.2%
$4.14M
−$10.03M
'24 Q2
24-05-08
▲18.3%
$3.95M
−$10.97M
'24 Q3
24-08-08
▼100%
$
−$7.90M
'25 Q2
25-05-08
LATEST
▼100%
$
−$7.33M
'25 Q3
25-08-12
Conference
Investor event
2026-08-12
Veru Inc. (VERU) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-08-10
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Confident tone
Novo Nordisk clinical supply agreement
GLP-1 weight loss plateau problem
Commercial market opportunity and Medicare reimbursement
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-05-13
Veru Inc. (VERU) Q2 2026 Earnings Call Transcript
Confident tone
Sarcopenic obesity in older patients
Enobosarm Phase 2b Quality trial results
GLP-1 receptor agonist limitations
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-02-26
Veru Inc. (VERU) February 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-02-11
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Confident tone
Novosarm obesity program
Phase 2b PLATO study design
Bone mineral density opportunity
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-09-30
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Confident tone
Enobosarm Phase IIb trial results
FDA regulatory guidance and pathway
PLATEAU Phase IIb clinical trial design
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-08-12
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Confident tone
Inovasaram Phase 2b QUALITY trial efficacy
Physical function preservation (stair climb)
Maintenance extension / weight regain prevention
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-05-08
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
Confident tone
Enobosarm + GLP-1 obesity program
Physical function (Stair Climb)
Body composition / tissue-selective weight loss
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-02-13
Veru Inc. (VERU) Q1 2025 Earnings Call Transcript
Confident tone
Enobosarm Phase 2b QUALITY study results
Phase 2b extension study
Sabizabulin in atherosclerotic cardiovascular disease
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-08-08
Veru Inc. (VERU) Q3 2024 Earnings Call
Revenue
$3.95M
▲ 18.3% YoY Gross margin
33.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-05-08
Veru Inc. (VERU) Q2 2024 Earnings Call Transcript
Positive tone
Enobosarm for high-quality weight loss (with GLP-1)
Phase IIb clinical trial design and endpoints
Unmet need around muscle loss on GLP-1 drugs
Revenue
$4.14M
▼ 37.2% YoY Diluted EPS
$-0.70
Gross margin
16.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-02-08
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
Confident tone
Enobosarm for high-quality weight loss with GLP-1
Phase IIb clinical trial design and milestone
GLP-1 muscle loss unmet medical need
Revenue
$2.14M
▼ 14.6% YoY Diluted EPS
$-0.80
Gross margin
53.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-08-10
Veru Inc. (VERU) Q3 2023 Earnings Call Transcript
Revenue
$3.34M
▼ 65.2% YoY Diluted EPS
$-1.40
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-05-11
Veru Inc. (VERU) Q2 2023 Earnings Call Transcript
Revenue
$6.59M
▼ 49.4% YoY Diluted EPS
$-4.20
Gross margin
62.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-02-09
Veru Inc. (VERU) Q1 2023 Earnings Call Transcript
Revenue
$2.51M
▼ 82.3% YoY Diluted EPS
$-4.80
Gross margin
28.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-05
Veru Inc. (VERU) Q4 2022 Earnings Call Transcript
Revenue
$2.59M*
▼ 83.5% YoY Gross margin
19.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-08-11
Veru Inc. (VERU) Q3 2022 Earnings Call Transcript
Revenue
$9.60M
▼ 45.6% YoY Diluted EPS
$-2.80
Gross margin
73.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-05-12
Veru Inc. (VERU) Q2 2022 Earnings Call Transcript
Revenue
$13.03M
▼ 2.3% YoY Diluted EPS
$-1.80
Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-02-09
Veru Inc. (VERU) Q1 2022 Earnings Call Transcript
Revenue
$14.14M
▼ 3.3% YoY Diluted EPS
$-0.80
▼ 134.8% YoY Gross margin
83.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-02
Veru Inc. (VERU) Q4 2021 Earnings Call Transcript
Revenue
$15.65M*
▲ 33.2% YoY Gross margin
78.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-08-12
Veru Inc. (VERU) Q3 2021 Earnings Call Transcript
Revenue
$17.66M
▲ 71.1% YoY Diluted EPS
$-0.30
Gross margin
78.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-05-12
Veru Inc. (VERU) Q2 2021 Earnings Call Transcript
Revenue
$13.34M
▲ 34.2% YoY Diluted EPS
$-0.40
Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-02-10
Veru Inc. (VERU) Q1 2021 Earnings Call Transcript
Revenue
$14.62M
▲ 38.2% YoY Diluted EPS
$2.30
Gross margin
74.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-09
Veru Inc. (VERU) Q4 2020 Earnings Call Transcript
Revenue
$11.75M*
▲ 34.6% YoY Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-08-13
Veru Inc. (VERU) Q3 2020 Earnings Call Transcript
Revenue
$10.32M
▲ 6.1% YoY Diluted EPS
$-0.50
Gross margin
63.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-05-13
Veru Inc. (VERU) Q2 2020 Earnings Call Transcript
Revenue
$9.94M
▲ 42.5% YoY Diluted EPS
$-0.10
Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-02-12
Veru Inc. (VERU) Q1 2020 Earnings Call Transcript
Revenue
$10.58M
▲ 66% YoY Diluted EPS
$-0.50
Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 webcasts